AbCellera Biologics Inc.

11.32-0.0100-0.09%Vol 1.66M1Y Perf -27.42%
Aug 5th, 2022 16:00 DELAYED
BID11.21 ASK11.36
Open11.12 Previous Close11.33
Pre-Market- After-Market11.35
 - -  0.03 0.27%
Target Price
23.40 
Analyst Rating
Strong Buy 1.00
Potential %
106.71 
Finscreener Ranking
★★★★★ —    66.93
Insiders Trans % 3/6/12 mo.
100/100/60 
Value Ranking
★★★★+     59.55
Insiders Value % 3/6/12 mo.
100/100/0 
Growth Ranking
★★★★★     85.71
Insiders Shares Cnt. % 3/6/12 mo.
100/100/35 
Income Ranking
 —    -
Price Range Ratio 52W %
34.28 
Earnings Rating
Market Cap3.22B 
Earnings Date
9th Aug 2022
Alpha-0.05 Standard Deviation0.21
Beta-1.35 

Today's Price Range

10.8711.66

52W Range

5.4222.63

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Strong Buy
Performance
1 Week
12.75%
1 Month
6.99%
3 Months
52.15%
6 Months
21.72%
1 Year
-27.42%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ABCL11.32-0.0100-0.09
AAPL165.35-0.2300-0.14
GOOG118.22-0.6500-0.55
MSFT282.91-0.7400-0.26
XOM88.451.26001.45
WFC43.760.99002.31
JNJ171.11-0.6800-0.40
FB196.640.99000.51
GE74.360.69000.94
JPM115.763.40003.03
 
ProfitabilityValueIndustryS&P 500US Markets
85.70
60.00
63.70
-
45.14
RevenueValueIndustryS&P 500US Markets
461.40M
1.62
304.13
-
Earnings HistoryEstimateReportedSurprise %
Q01 20220.470.5414.89
Q04 20210.210.19-9.52
Q03 2021-0.05-0.08-60.00
Q02 20210.09-0.01-111.11
Q01 20210.370.370.00
----
----
----
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date9th Aug 2022
Estimated EPS Next Report0.04
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume1.66M
Shares Outstanding284.54K
Shares Float151.58M
Trades Count17.76K
Dollar Volume18.93M
Avg. Volume1.97M
Avg. Weekly Volume1.59M
Avg. Monthly Volume1.67M
Avg. Quarterly Volume2.64M

AbCellera Biologics Inc. (NASDAQ: ABCL) stock closed at 11.32 per share at the end of the most recent trading day (a -0.09% change compared to the prior day closing price) with a volume of 1.66M shares and market capitalization of 3.22B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 174 people. AbCellera Biologics Inc. CEO is Carl L.G. Hansen.

The one-year performance of AbCellera Biologics Inc. stock is -27.42%, while year-to-date (YTD) performance is -20.84%. ABCL stock has a five-year performance of %. Its 52-week range is between 5.42 and 22.6337, which gives ABCL stock a 52-week price range ratio of 34.28%

AbCellera Biologics Inc. currently has a PE ratio of 16.40, a price-to-book (PB) ratio of 2.48, a price-to-sale (PS) ratio of 6.44, a price to cashflow ratio of 14.20, a PEG ratio of 2.32, a ROA of 15.41%, a ROC of 18.42% and a ROE of 19.40%. The company’s profit margin is 45.14%, its EBITDA margin is 63.70%, and its revenue ttm is $461.40 Million , which makes it $1.62 revenue per share.

Of the last four earnings reports from AbCellera Biologics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $0.04 for the next earnings report. AbCellera Biologics Inc.’s next earnings report date is 09th Aug 2022.

The consensus rating of Wall Street analysts for AbCellera Biologics Inc. is Strong Buy (1), with a target price of $23.4, which is +106.71% compared to the current price. The earnings rating for AbCellera Biologics Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

AbCellera Biologics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

AbCellera Biologics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 22.78, ATR14 : 0.60, CCI20 : 105.35, Chaikin Money Flow : -0.01, MACD : 0.25, Money Flow Index : 61.88, ROC : 6.29, RSI : 47.14, STOCH (14,3) : 81.19, STOCH RSI : 0.99, UO : 57.01, Williams %R : -18.81), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of AbCellera Biologics Inc. in the last 12-months were: Andrew Booth (Buy at a value of $1 485 280), Carl L.G. Hansen (Option Excercise at a value of $3 677 310), Ester Falconer (Option Excercise at a value of $14 778 750), John Edward Hamer (Sold 300 000 shares of value $5 082 252 ), John S. Montalbano (Buy at a value of $369 780), Michael Hayden (Option Excercise at a value of $4 787 100), Veronique Lecault (Buy at a value of $3 266 412), Veronique Lecault (Option Excercise at a value of $1 294 161)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (100.00 %)
5 (100.00 %)
5 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.00
Strong Buy
1.00
Strong Buy
1.00

AbCellera Biologics Inc.

AbCellera Biologics Inc is a biotechnology company. The company develops antibodies to treat highly infectious diseases and various other types of diseases.

CEO: Carl L.G. Hansen

Telephone: +1 604 559-9005

Address: 2215 Yukon Street, Vancouver V5Y 0A1, BC, CA

Number of employees: 174

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

57%43%

Bearish Bullish

62%38%

Bearish Bullish

60%40%

TipRanks News for ABCL

Wed, 11 May 2022 12:49 GMT AbCellera Biologics (ABCL) Receives a Buy from SVB Securities

- TipRanks. All rights reserved.

News

Stocktwits